Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often precedes further gains.
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.
Health Rounds: Experimental Sanofi drug delays heart valve disease progression, and potentially surgery
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, researchers reported.
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi in its ability to dramatically boost the productivity of researchers. Sanofi's strong financials provide a solid base to fuel AI-driven growth.
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
Sanofi (SNY) Q4 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Houman Ashrafian - Executive Vice President, Head of Research and Development Conference Call Participants Luisa Hector - Berenberg Graham Parry - BofA Seamus Fernandez - Guggenheim Peter Welford - Jefferies Jo Walton - UBS Richard Vosser - JPMorgan Florent Cespedes - Bernstein Securities David Risinger - Leerink Peter Verdult - BNP Exane Emmanuel Papadakis - Deutsche Bank Eric Berrigaud - Stifel Ricardo Benevides - Santander Thomas Larsen Welcome to the Q4 and Full Year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance
Sanofi CEO Paul Hudson discusses the company's quarterly earnings results and his thoughts on the confirmation hearing of RFK Jr.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmation hearing of RFK Jr., and more.
